and a member of our team will be happy to help you.

© transcript Emily Beynon © transcript Emily Beynon © BF-WATCH TV 2021 ¶¶ ¶¶ © BF-WATCH TV 2021

Thank you. © BF-WATCH TV 2021 Good evening, ladies and gentlemen, and welcome to the Verica Pharmaceuticals third quarter 2026 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference.

Thank you, operator. Hello, everyone, and welcome to Verica Pharmaceuticals Third Quarter 2026 Corporate Update Conference Call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, and Chris Chapman, Chief Commercial Officer. As a reminder during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verica's SEC filings for important risk factors. Verica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations. In addition, during today's call, management will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures compared to their closest GAAP equivalents. The earnings release that the company issued today includes GAAP to non-GAAP reconciliations for these measures and is also available on the investor relations section of Verica's website. I'll now turn the call over to Verica's President and CEO, Jason Rieger.

Thank you, Kevin. Good evening, everyone, and thank you for joining us for our third quarter 2026 Corporate Update Call. We're so proud of our team's performance in the third quarter, as our commercial organization generated record Y-CANTH revenue for the second quarter in a row, while our research and development teams made major progress in our Global Phase III program to expand Y-CANTS label to common warts, the largest unmet need in dermatology by prevalence. During the quarter, we announced the completion of enrollment in the first pivotal trial in the phase three program and greater than 50% enrollment in the second pivotal trial. Progress in each trial brings us closer to a possible expansion of Y-CANTS label into what we believe could be a multi-billion dollar market for common warts. Following the end of the quarter, we announced that we have unlocked the remaining $15 million of borrowing commitment from the credit facility we entered into in August as we met the predefined operational and performance milestones established in the facility. The non-dilutive capital now available to draw, as needed, is expected to allow us to complete both pivotal studies in the CommonWords program with readouts from the studies expected in the first quarter and in mid-2027, respectively. Finally, I'm excited to share that we are now exploring the development of VP315 to treat patients with Gorland syndrome. a rare genetic disease causing dozens or hundreds of basal cell carcinomas or BCCs over the patient's lifetime, often presenting them with substantial surgical fatigue and extensive scarring and for which there are currently no approved therapies. Our foundational data in sporadic BCC provides promise for the potential benefit of VP315 for Gorlin patients, and we will provide more details about our plans as the clinical protocol, budget, and timelines are finalized. I will now discuss in more detail our commercial and clinical progress before turning the call over to Noah to provide some additional detail From a commercial perspective, in the third quarter of 2026, total revenue was $6.9 million, including a record U.S. Y-CAMP net product revenue of $5.7 million. This represents an increase of approximately 11.9% over the second quarter and a 57.9% increase over the third quarter of last year. In the third quarter, dispensed applicator units for YCAMS totaled 19,135, down 491 units from the previous quarter and up 35.8% or 5,042 units from the third quarter of last year. We believe this decrease reflects summer travel seasonality impacting both patients and providers. The strong year-over-year revenue and unit growth reflects the continued successful execution of our commercial strategy based on expanding YCAMP distribution through both the specialty and retail pharmacy channels, which allows continued penetration into high-volume prescribers across dermatology, pediatric, and primary care offices. Consistent with the second quarter, we continue to generate strong growth demand from commercially insured patients, where our co-pay assistance programs play a critical role enabling patient access to Y Camp. As always, our goal is to maximize patient access to what we believe is the most effective therapy in the treatment of molluscum, Y Camp, and we continue to work to anticipate and remove as many barriers to access as possible. With our prescriber retargeting and segmentation work that we discussed on our second quarter call now in place, we have turned our focus to driving both volume and yield and have undertaken efforts to reduce prescription leakage and ensure optimal insurance coverage. The efforts that began with our Y Camp Rx non-dispensing pharmacy option, as well as other initiatives, have matured. and during the third quarter, we began to realize the benefits of these efforts with an improvement in yield per prescription. With regards to Y-cams for molluscum, we continue to believe the largest competitive challenge is the historically entrenched watch and wait mindset that exists before any FDA approved therapies were available. We must work to ensure that patients with molluscum now realize that they have access to a highly effective treatment option Thank you for joining us today. and three times as many Y-CAMP-treated patients achieved complete clearance at each treatment visit. We believe these data analyses strongly support the practice of treating molluscum earlier in the course of infection rather than simply taking a watch and wait approach that was common before Y-CAMP was approved. Since announcing in July our exclusive distribution, marketing and supply agreement with Madomi Pharma, to commercialize YCAMP in Israel, we have been working with Madomi on their preparation activities to seek approval for YCAMP. We are pursuing many global expansion opportunities for YCAMP as molluscum appears to affect children globally irrespective of race, gender, or socioeconomic situation, and we see continued interest from potential partners around the world. Turning to our pipeline, we made major progress in our global phase three program studying why cancer treatment of common warts during the third quarter. In August, we announced the completion of enrollment in COVE-2, the first pivotal phase three trial, after an interim analysis confirmed that no additional patients were recommended for enrollment. We expect top line data from COVE-2 to be available in the first quarter of 2027. Our clinical team has also enrolled patients in COVE-3, our second pivotal phase three trial, ahead of schedule. And in late August, we announced that enrollment has exceeded 50% of its current target. We expect top line data from this trial to be available by mid-2027. As a reminder, we are conducting the global phase three program with our development partner, Torrey Pharmaceutical, which is funding the first 40 million of trial costs. representing approximately 90% of the current program budget. Research and development expenses for the program have been non-cash to date and will continue to be non-cash until Tori's funding commitment is exhausted towards the end of the program. Common Warts affects approximately 22 million people in the U.S. alone, and there are no FDA-approved prescription therapies today. We believe label expansion of WICAMP into common warts could represent a multi-billion dollar commercial opportunity. Given the substantial overlap of clinicians who see molluscum patients and also treat common warts, we believe that we could realize substantial commercial synergies from our existing commercial infrastructure upon launching into common warts, if approved. With respect to our VP315 program for basal cell carcinoma, we continue to believe this asset has the potential to change the paradigm for treatment of BCC. In September and October, we present an encore poster at scientific conferences describing an exploratory analysis of potential abscopal-like effects of VP315. I will now ask Noah to add further commentary on our VP315 program and its potential to help patients with Gorlin syndrome.

Thank you, Jason. I'm pleased to share a program update regarding VP315, namely that we were exploring a proof-of-concept study of VP315 in patients with Gorlin syndrome. As I'll discuss more shortly, Gorlin patients live with a relentless burden of frequent basal cell carcinomas, and we believe VP315 could change their treatment paradigm. Gorlin syndrome is also called basal cell nevus syndrome is a rare genetic disorder usually caused by a mutation in the patch one or PTCH1 gene that over activates the hedgehog signaling pathway. Patients can develop dozens to hundreds of BCC lesions over their lifetime, often starting in their teens or younger. Because new BCCs continue to appear and patients who are highly sensitive to radiation, they often face a lifetime of repeated destructive surgical procedures which leave cumulative scarring and disfigurement along with a heavy psychological and quality of life burden. Oral hedgehog inhibitors can help somewhat but are not approved for this indication and side effects to these drugs such as muscle cramps, hair loss, and Lost of Taste make their long-term use hard to tolerate. As I've said today, there is no therapy that is FDA approved specifically for the use in patients with Gorlin Syndrome. Gorlin Syndrome is a rare disease with a prevalence of an estimated 11,000 patients in the U.S. The Gorlin patient community has desperately sought an effective, safe and tolerable non-surgical treatment option since the standard of care is so taxing. In this population, Gorlin experts have told us that even a modest reduction in the size and or number of lesions could have a profound impact on patient quality of life and surgical burden. In our previously disclosed phase two study of VP315 for the treatment of sporadic BCC, injections of VP315 produced a 97% objective response rate and an average 86% reduction in tumor size in treated lesions with histological confirmation of complete clearance in over half of the subjects. In addition to these results in primary treated lesions, untreated lesions, which in some cases were distant to the primary injection site, also shrank by an average of 67%. of the 14 lesions in patients with additional untreated lesions cleared completely, further suggesting a potential abscopal response. The positive results observed in both primary and abscopal lesions are supportive for optimism that the sporadic BCC results may translate to patients with Gorlin syndrome. As we also previously disclosed, We reached agreement with the FDA on design of a Phase III program to study BP315 for sporadic BCC, consisting of two 100-patient placebo-controlled studies with long-term follow-up to be conducted post-approval. Our discussions with the FDA led to alignment on the sporadic BCC Phase III study design, and the agency specifically asked that we include Gorlin patients in our phase three protocol given the significant unmet need of these patients. As Gorlin patients were excluded in our phase two study, a first evaluation of VP315 in this patient population would be an important step in optimizing our overall development as well as to confirm the benefit in this more severe population. Since our FDA meeting, The feedback we have received from key opinion leaders and treating clinicians has been very supportive. Experts have urged us to study VP315 in patients with more severe disease, especially those worn down by repeated destructive therapies and surgeries. By studying patients with a heart disease burden, we can learn more about the potential of scopal effect and explore whether repeat dosing can provide even better efficacy than a single cycle dosing regimen. Gorlin syndrome patients are the clearest population to demonstrate the impact that VP315 can have on patients with large quantities of BCC lesions. In our outreach to Gorlin syndrome experts, both clinicians and patient advocacy groups said that there was real excitement about VP315. Based on our Phase 2 findings, they believe VP315 has the potential to deliver meaningful lesion reduction and positively impact quality of life in these patients. We are now finalizing the study design, drafting the protocol, and estimating the cost of a potential Gorlin study, which would use clinical supply we have now manufactured. We expect this study could complement Our understanding of BP315, including its potential of scopal effect, and we believe BP315 could become a differentiated treatment option for this patient population with significant unmet need. Having experienced successfully developing drugs in rare disease, I have learned about the challenging journey these patients and families endure and have a passion for developing effective therapies for these underserved patients with high unmet need. I am looking forward to sharing more as we finalize the protocol and the next steps necessary to start the study. I'll now turn the call back over to Jason.

Thanks, Noah. Before turning the call over to John, I'd like to spend a few moments on the additional commitment now available to us under our credit facilities. As you will recall, in August, we closed a credit facility of up to $27.5 million with an entity controlled by Paul Manning, our chairman and largest shareholder, of which $12.5 million was immediately available and the remaining $15 million would become available upon achievement of certain predefined revenue, growth, and operational milestones. In late October, We announced that Verica achieved these milestones and has increased the maximum commitment amount under the facility. We reached these milestones based on the momentum that our commercial team has built with Weikant. Importantly, the flexibility afforded to us under this credit facility provides Verica with the ability to draw funds when needed and not carry the entire debt burden from the initial closing. The additional capital from the credit facility will allow us to complete our two pivotal studies in the CommonWorks program and evaluate the data from these studies, which, as I mentioned earlier, are expected to be released in the first quarter and in mid-2027, respectively. In summary, we are now well-positioned to continue investing across all of our strategic initiatives to grow value for our shareholders. I'll now turn the call over to our Interim Chief Financial Officer, John Kirby, to review the third quarter 2026 financials.

Thanks, Jason. I'll now take a few minutes to summarize our financial results for the third quarter ended September 30th, 2026. Total revenue for the third quarter of 2026 was $6.9 million, compared to $14.3 million of total revenue for the third quarter of 2025. As you will recall, revenue for the third quarter of 2025 included a one-time milestone payment from Tory of $10 million earned in connection with the approval of Wycanth for Molluscum in Japan. U.S. net Wycanth product revenue was $5.7 million in the third quarter of 2026 compared to $3.6 million in the third quarter of 2025. The increase was primarily related to increased deliveries of Wycanth to our distribution partners and increased yield resulting from improved commercial execution. Licensing collaboration revenue was $1.2 million, consisting primarily of commercial supply for Tori's Wycanth launch in Japan, compared to $10.7 million in the third quarter of 2025, which again included the one-time payment of $10 million. Net Wycanth revenue in the third quarter of 2026 reflects shipments to our distribution partners offset by standard gross-to-net adjustments, including actual or anticipated product returns, off-invoice discounts, distribution fees, rebates, and copay assistance program expenses. Gross product margins for the third quarter of 2026 were 89.8% compared to gross product margins of 79.1% in the third quarter of 2025. Cost of product revenue for the third quarter of 2026 was $0.6 million versus $0.8 million in the third quarter of 2025. Research and development expenses were $7.6 million in the third quarter of 2026, compared to $2.2 million in the third quarter of 2025. Excluding the impact of stock-based compensation, the increase of $5.2 million was primarily attributable to an increase of $3.7 million in costs associated with the Phase III program for common warts. As a reminder, The expense for the Phase 3 Commonwealth Program did not impact our cash balance, as the first $40 million of payments for this program will be made by Torrey. There was also an increase of $1.3 million of expense related to chemistry manufacturing and controls across Wycanth and VP315. Selling general and administrative expenses were $10.4 million in the third quarter of 2026 compared to $9.4 million in the third quarter of 2025. Excluding the impact of stock-based compensation, these expenses were comparable to the prior year period. Interest income was $45,000 in the third quarter of 2026 compared to $0.2 million in the third quarter of 2025. Interest expense was $0.3 million compared to $2.1 million in the same period last year, with the decrease of $1.8 million related to the settlement and termination of our Orvumed debt facility in November of 2025. Gap net loss was $12.4 million or 58 cents per share for the third quarter of 2026 compared to gap net loss of $0.3 million or 3 cents per share for the third quarter of 2025. On a non-gap basis, which excludes stock-based compensation, change in fair value of derivative liability and non-cash interest expense, the third quarter of 2026 net loss was $10.5 million, or 49 cents per share, compared to non-GAAP income of $1.1 million, or 12 cents per share, for the third quarter of 2025. And finally, as of September 30, 2026, Verica had cash of $14.4 million, which includes the $12.5 million borrowing from the credit facility in the third quarter. Assuming utilization of the remaining $15 million available under the credit facility, we believe our cash runway could extend beyond our key data readouts for common warts and into the fourth quarter of 2027. As we noted, we're in the process of designing a proof of concept study in Gordland syndrome, and as we finalize our plans, We will include any trial costs in our operating plan in future periods. I'll now turn the call back over to Jason for closing remarks.

Thanks, John. To recap, in the third quarter, we experienced record quarterly Y-CANTH revenue amid strong year-over-year growth in units, and we are encouraged by these demand trends. We believe that Y-CANTH is the best treatment option for patients with molluscum and our new post hoc pooled analysis from WICAMS Registrational Studies reinforces the benefit of early and aggressive treatment interventions with WICAMS. We made progress towards a potential WICAMS label expansion in common warts with the completion of enrollment in COVE-2 and greater than 50% enrollment in COVE-3 with expected top line data in Q1, 2027 and mid-2027 respectively. We believe common warts could represent a multi-billion dollar opportunity for Y-CAMP if approved. Collectively, our commercial foundation, potential label expansion, and our pipeline provide a compelling future for Verica and the patients our therapies can benefit. Finally, with full access to our credit facility, We have the cash runway that enables us to see through our phase three common warts program to data readouts for both of our pivotal studies. We're excited about our progress across the YCAM franchise and the potential for VP315 to help patients with Gorlin syndrome and sporadic BCC and look forward to sharing further updates. With that, we'd be happy to answer your questions. Operator?

Thank you. If you'd like to ask a question, press star 1 on your keypad. To leave the queue at any time, press star 2. Once again, that is star 1 to ask a question. And we'll take our first question from Stacy Q. with T.D. Cowan. Your line is open.

Thanks so much. Congratulations on the progress. We do have a few questions. First for Jason and Chris. Maybe a big picture as we think about 2027, what do you think will be the growth drivers for Weikamp and Molluscum? That's the first. And then to kind of drill down a little bit more, just maybe give us an update on how access is progressing. Could we expect any improvements in pharmacy versus medical coverage for Weikamp just to stay competitive? That's the second question. And then, of course, as we think about the broader seasonality you're observing for Molluscum, as we looked at just Q4, maybe just help us guide what your expectations are, especially with what seems to be improvement in that pricing. So that's questions for why can't. And then Noah, appreciate the update for BP315, an announcement to pursue development in Gorlin syndrome. Maybe discuss next steps in a little bit more detail to clarify would you be trying to pursue a phase two POC? Thanks so much.

Thank you, Stacy. Appreciate the call, and we're certainly excited about the progress we've been making over the last several quarters on these programs. Certainly saw growth in the demand for YCANTH, but also working towards optimization and the coverage access and reimbursement for the YCANTH program, and some of the initiatives that we've spoken about in the past are certainly starting to work pretty well. I'll hand over to Chris and let him comment a little more on what we're using for the growth drivers and how we see that growing going forward and how we're working on access and some of the impacts we see on seasonality.

Thanks, Jason. And, Casey, thanks for the question. The growth drivers is really straightforward. When you think about, you know, Q2, we had the discussion about taking a real close look and a complete revamp of our targeting and segmentation. We're starting to see the benefits of that now, and we're starting to move prescribers from the dabbler phase into the stronger adoption and, of course, loyalist. One of the key parts, and this is where it's really good to have competition in the market with a second manufacturer, is you have to prospect in a market like this where your largest hurdle is watchful waiting, you know, decades of watchful waiting. We're seeing that change right now and we're seeing it specifically in high volume pediatricians. So certainly one of the big growth drivers is to continue to move our dabblers up the continuum to be loyalists. We have a very robust conversion rate now that we saw in Q3. We're hoping to drive that into Q4 and then, of course, mature that in 2027. The other from a net revenue perspective, you saw the early indications in this quarter in our efficiency, is putting in place a fulfillment platform that can handle both medical coverage as well as pharmacy coverage. And that really ties into your, I think it was your second or third question, you know, in terms of coverage. Right now, We have, according to MMIT, 95 million lives covered under pharmacy and 137 under medical. You know, one of the things that's very, very obvious to me is whether it's pharmacy or medical coverage, they are not draconian restrictions that we're getting through. But we do need to get the prescriptions, specifically if it's a medical benefit, into a channel, into a network pharmacy that that particular payer will reimburse for. So that's one of the key strategies that we've been focused on. And again, you see the benefits in this past quarter in terms of accreting yield. So we hope to mature that. That'll be another key growth driver combined just with our efficiency of moving the physicians up the adoption curve. So I'll pause there. I believe that got to your two questions.

Yes.

Yeah, seasonality, I think you do see, like we saw in Q3, and it's really more consumer seasonality, you do see fewer office hours, and we will see that in Q4, and you do see changes in consumer patterns in people seeking treatment. So I would expect in Q4 we'd see normal seasonality patterns, but again, You know, we're looking to continue to drive the value of each possible prescription and continue to grow the brand.

Thank you for all the . And Noah.

Thank you, Chris. One second, Stacy. The only thing I would add to what Chris commented on, what's going to drive the growth, I think it's also continued awareness about the clinical and safety benefits of Y Camp, especially over the watchful waiting mindset and the fact that we can drive a much higher rate of clearance and benefit for these patients versus asking them to suffer with this disease for up to 12 or 18 months or longer. So I think part of the driver is going to be that continued education about the clinical and safety benefits. and now Noah, I'll ask you to sort of comment on the sort of broader strategy for VP315, but it's important as we think through this and understanding the primary data we've already observed, you have scopal data we think we've seen in the pilot study and how this population, this data will advance our knowledge of 315 and support the broader program. But Noah, please add some color commentary for Stacy.

Sure, great question, Stacy. Happy to provide some color here. As you recall, during our discussions with the FDA, which led to alignment on the sporadic BCC Phase III study design, the agency specifically asked that we include Gorlin patients in our Phase III protocol, and that's because of the significant unmet need of these patients. These patients can see, on average, over 200 lesions in a lifetime, so there's a very, very high unmet need. And as Gorlin patients were excluded in our Phase II, although we think that data is extremely important as a foundation, If we can translate those results into a proof of concept as a first evaluation of 315 in this patient population, we believe that would be a really important step in optimizing development and confirming benefit in this population. So to that end, we're finalizing study design, we're drafting protocol, estimating costs, et cetera, and we have the clinical supply on hand. Just to close, we really expect this study could deepen our understanding of VP315. As Jason alluded to, the potential of scopal effect translating into ghrelin, which would be extremely clinically meaningful as we've talked to KOLs and advocacy folks. And we believe that 315 has the potential to become a very differentiated treatment or a very important treatment for this population with a high unmet need. I look forward to sharing more as we finalize the protocol and the next steps necessary to start the study. Thank you.

Thank you. We'll take our next question from Dennis Ding with Jefferies. Your line is open.

Hey, guys. I have two questions both on the Common Worse Program. So, number one, can you go into more detail about the interim analysis that occurred over the summer? That included a futility analysis as well, meaning the fact that the DSMB didn't stop the trial for futility implies that there's a signal. If they didn't recommend more patients, that may imply that the signal should look in line with what you guys expected in your protocol and that there's enough power to detect it. So do you think that we're thinking about that the right way? And then question number two, remind us what standard of care right now is for common wards and if there's documented data on complete clearance and if that's the hurdle that you'll need to get over to get favorable reimbursement and be used commercially. Thanks so much.

Thank you, Dennis. Appreciate the questions. I'll let Noah take the question on sort of the interim analysis as we'll provide clarity for you.

Great question, Dennis. So in terms of the interim analysis, we did not include a specific futility analysis there. It's a blinded review. It's called a promising zone analysis. What we saw there in COVE-2, for instance, when we do that analysis, it suggests that there's not a need for additional patients. The agency has reviewed this analysis and agreed, and it's conducted by an independent statistician, and the company and study team remain blinded to it, so it's a very specific analysis looking at conditional power, ensuring that you have enough power to complete the study. And basically, either, if you don't increase the number of patients, There's either the potential that you've got enough patients and you're going forward. There's also the opportunity and potential that you could not have an ability, despite increasing the total number of patients, to get over that hurdle from a power standpoint. So those are two scenarios. But we're very encouraged by the fact that we didn't need any additional patients. And based on the Phase II results, we're encouraged, and we've seen the drug work in the past. So that's as much as I can say right now on the air analysis.

Thank you. And then you'll just add some comments here on the standard of care and sort of what we're thinking about for efficacy hurdle.

So I'll just add, in terms of the standard of care, keep in mind that right now we have no approved therapies for common warts. There's nothing. Despite the fact that it's a 22 million patient a year population, It really gives pause, and you realize how difficult and challenging that this disease is to treat. It's very stubborn. And I would say what we're looking to assess with the pivotal data, instead of anchoring to sort of a single numerical threshold, I think we're looking for a clear, consistent improvement in complete clearance and percent reduction over vehicle that's clinically meaningful and significantly significant over vehicle with acceptable safety and tolerability. I think that's the goal. Again, with no approved therapies and current surgical treatments are inadequate. They are often painful. They can cause scarring, discoloration, et cetera. We think that the data here could offer a great potential for patients and physicians.

And while Noah and the clinical team have done a tremendous job of recruiting in this study and advancing this program, the fact that we were able to recruit these studies as effectively as we did into a placebo-controlled trial sort of speaks to that unmet need and patients really looking for some type of treatment option given that the standards of care really aren't adequately addressing their disease.

Okay, thank you. Thank you, Dennis.

We'll take our next question from Ram Selvaraju with HC Wainwright. Your line is open.

Thanks so much for taking our questions. Firstly, with respect to YCAN, can you just give us a sense of how we should be thinking about ex-US revenue that you report on the P&L and if you anticipate on a go-forward basis sequential quarter-over-quarter growth on that line? primarily based on, of course, what you're seeing from Tory in Japan, or if we should be thinking about the third quarter number as being reflective of any stocking impact that might not necessarily be seen in the fourth quarter. And then wanted to see if within the context of Gorlin syndrome, if you could comment on the competitive landscape there, particularly how you anticipate your candidate might potentially play alongside hedgehog inhibitors. If you anticipate that these could be deployed synergistically or to what extent, from a competitive standpoint, the Gorlin Syndrome indication might be affected in terms of attractiveness by the potential entry of new hedgehog inhibitor drugs. Thank you.

Sure. I'll start with the YCAMP, you know, I appreciate it, Ram. The YCAMP XUS revenue and then, you know, John can add some commentary on how the accounting works for that. But most, as you will recall, we have our collaboration in financing agreement with Tory to support our common work study. So most of the revenues there are reflecting the commercial supply to them and then offset by reimbursing us for cost of goods to provide them their commercial material. We will supply them as needed. They provide us Thank you for joining us today.

Similar, but probably a little less. As you may recall from our amended agreement, we will start, as they take over their own production in Japan, we will supply them with ampules, and they'll manufacture from that point on, and it will shift to a royalty basis. So hopefully that answers your question.

That's very helpful. Thank you. Okay, and then with regards to your Gorlin question, I think it's really interesting as we think about that landscape and the unmet need for those patients currently with nothing approved. You know, you do speak to there are both oral hedgehogs and, you know, topical hedgehogs, you know, in development, you know, with potential data readouts later this year. As we think about the modality of this product, PP315, for this patient population, it's independent of the hedgehog pathway based on what we saw in our sporadic BCC data. And our drug does a primary lytic approach towards eliminating the existing lesions that are treated with the potential for abscopal effect. Some of those other therapies are targeted towards reduction in the occurrence of new lesions, but you still have the remaining underlying lesions There certainly is the potential for complementary benefit for these patients to mitigate the need for surgery given the surgical burden they already endure. But, Noah, if you want to add some more commentary to that, please do so.

Yeah, I think it's a great question, and I think we're at a great opportunity now. To Jason's point, you know, we have no currently approved therapies for Gorlin Syndrome. The patients, as we mentioned earlier, have a high burden of disease. and great degree of Mohs fatigue, essentially, or surgical fatigue. I think the oral hedgehogs, while they can be effective, are limited by tolerability issues, GI, taste, et cetera. And so it's difficult to get patients to take those long term. I think the Sol-gel approach is a novel one. It's interesting, topical. And I think the avenue that they're approaching is prevention. of new lesions. Certainly, they're not curative. They're going to slow progression, hopefully. So the more therapies in the field, it often in these diseases requires multiple therapeutic options to address the unique challenges of each patient. So I see it as synergistic. As Jason alluded to, for VP315, I think we've got a lytic and an immunologic effect. So the lytic effect, you reduce primary lesions. The immunologic effect, you actually may be leading to a mescopal effect. And there's even some animal data in our program where we may have even seen a vaccine effect in prevention of new lesions. So again, I think they all can work together synergistically. And it's a great, great moment for patients with Golan, hopefully, with some positive data coming up.

And then just very quickly, can you give us a sense of how prescribers are reacting to the pooled analysis data from the Registrational Program in Molluscum and to what extent, if at all, this is coloring their willingness to prescribe Y-CAMP?

That's a great question. So just as a reminder, you know, we did a pooled analysis of the two Pivotals. We saw patients achieved complete clearance faster 4 times faster in the Y-CANTH group than the placebo group and 3 times as many Y-CANTH treated patients achieve complete clearance as well. You know, as I think it's been alluded to earlier, one of the biggest hurdles that we have is the biggest competition in some sense is watch and wait. You know, where doctors sort of say, well, it's molluscum, I can watch, I can see how it goes and take my time with it. But I think these analyses really show an urgency to treat. They show the benefit of treating I think there's an increasing awareness of patients' desire and families' desire to treat these lesions and to ensure that they can get back to class, they can get back to gym, they can get back to swimming in the pool. There are certain avenues where they may have limitations. Certainly, the cosmesis and stigma of having this disease also can be really challenging with kids. We've had very positive feedback. on that data from our KOL network and our physicians. And we think it's really important data, and I think they would agree with that.

Chris, maybe you want to add any commentary as what you're hearing from the field and how you're using that message to help doctors begin to adopt Y-CAM?

And we'll take our next question from Serge Blandreau with Needham & Company. Your line is open.

Hi. I'm sorry. Good afternoon. A couple questions for us. First on why can'ts, just trying to reconcile the growth in sales during the quarter with the downtick in volume units. I assume there was some growth to net improvements. Was there also some changes to the co-pay assistance? And are these one-time benefits or they could continue into other quarters? and then for VP315, just trying to see if I understood correctly, you're now planning to potentially include the Gorlin Syndrome patients in a registrational phase three program. Did I hear that correctly? And what would that mean for potential timing to start this phase three program? Thanks.

Sure. Well, you know, so in general, you know, sort of on the YCAM side, you know, The gross to net improvement based on the efforts we're working on for yield and how the prescriptions are filled is one of the things we've been working on for quite some time after building the foundation of adoption and demand for the product. And I'll let Chris sort of comment on the initiatives he's been working on and that have been rolling out throughout the year that I think have led to this sort of improvement in yield and hopefully continue to grow through that in that category.

Thanks for the question. I mentioned it a little bit with Stacy's question. You know, one of the unique things with Why Can't that we can't forget, we have the unique benefit of meeting doctors where they are and also, you know, payers where they are. We have about a 50-50 split, medical benefit to pharmacy benefit. Doctors can initiate buy-in bill. What you're seeing a reflection of in that accretion of yield is directing medical benefit claims into in-network pharmacies who are capable of submitting that claim and getting reimbursement. So we ran a number of proof of concepts and clearly you see the results. So I think it's safe to assume as we turn this on at scale, we'll continue to see accretion and we'll continue to refine our pull-through strategies on those medical claims. And I mentioned also, we have tremendous access and many of these medical claims are also going through with no PA and very few restrictions. So part of the challenge is less clearing the PA and more getting into the right channel with a pharmacy who is in network within the payer.

Serge, with regards to your VP315 question, the FDA had originally asked that we include those Gorlin patients as they would certainly have a high interest in the potential of this therapy. As we've talked to our KOLs, advisors, the advocacy groups and others, and even the patients, you hear that there's real demand and that because of the number of lesions those patients present with, there's the ability to gather significant data that enhances our basic understanding of the drug and how much of an impact we can have on the broader clearance of BCC lesions. and so our current plan that we're exploring right now is to do a proof of concept to confirm the efficacy in these patients and how the data we saw in our sporadic would inform the treatment modality and then use that data to, you know, continue to advance, you know, on our pivotal phase three program, whether it stays, you know, Gorlin specific population, the sporadic population as We have alignment with the FDA on that activity, or perhaps both. I think there's real opportunity for this program, but this will help us with understanding and optimizing our treatment approach for treatment of BCCs with Gorlin. Noah, I don't know if you have any more to add to that, but I think that was the question SIRT is asking.

Yeah, I think the key is that it's not either or, Jason, to your point, right? We've learned in talking with Gorlin advocates and KOLs as recommended by the agency. We've learned that it's a huge unmet need and we really understand it a lot better now. And I think the goal is really to ensure that we understand that population and how the drug works in that population. And we believe the two can work together. I think we'll have, when we have the proof of concept data, we'll be able to assess and evaluate dosing strategies and different approaches of scopal effect, et cetera. So I think it'll be very encouraging and positive if we can get some good data in that population help propel the program forward, both in Gorlin as well as in BCC.

We'll take our next question from Thomas Flatton with Lake Street Capital. Your line is open.

Hey, everyone. Thanks for taking the questions. Just to follow on to that last response, So you will not initiate a phase three until you've completed the POC in Gorlin patients. Is that a fair read on the discussion so far?

Go ahead, Noah, please. No, you please. Okay, so I was going to say, in terms of that, the amount of data we can generate and how quickly we generate could inform that. You don't necessarily need to complete the entire study to initiate the phase three. I think we are a data-driven organization. We're going to focus on that data and let it inform the best way to optimize a final phase three protocol for sporadic PCC or move into the engagement with the agency on a pivotal phase three program for Gorlin or both. And I think we're going to let that data drive our further understanding. And it's driven by a lot of KOL feedback encouraging us to really emphasize on these patients with large numbers of lesions and high surgical fatigue. as a place to really differentiate the benefit of the drug, which would then roll down to those who have one or two lesions but still are adverse to getting surgery.

Got it. But just from a strategic perspective, then, just to continue that thought, if you did a Phase III study as planned with Gorlin patients included, per the FDA's request, Would that not give you a label that would include Gorlin? Maybe even if you over indexed a little bit on Gorlin patients, wouldn't that provide you sufficient data to still penetrate that market without doing a separate POC study or am I overthinking that?

I think you're partially correct on that front. The key thing is we wouldn't want to do that without having had some data in that population on the off chance that we're not correct and that patient population behaves differently. So by doing this open label, sort of a proof of concept data to confirm the efficacy, which we're highly confident on, but wouldn't want to do a blinded phase three study, especially with patients that really need medical intervention. And when you want to have confidence in the drug, we work for them. I think this will allow us to do that and also to follow those patients over a longer period of time to provide data updates as to the longer term benefit for those patients, all the while exploring the sporadic PCC which will certainly help advance the disease and understanding and also our conversations with KOLs and potentially payers down the road.

That's super helpful. Thank you for that. And then just one final one. Assuming success in the Common Warts program in a readout mid-27, can you give us a sense of what we should anticipate for regulatory submission on that? Do you think you can get that done by year-end 27th?

I would certainly ask you, I'm going to push very hard on our clinical team and our regulatory team and our CMC teams to be ready for the filing as quickly as possible. You want to see the data, you'll get it turned around and the team will focus and make every effort they can to achieve that as fast as possible. I won't put no on the spot on the call to answer your question directly, but I would say that we've been pushing them very hard. And as you can see from the data, we've dramatically exceeded our expectations on the enrollment. and the enrollment rates of that study. And our goal is to continue to push on that very quickly. You know, stay tuned as soon as when that data comes out and we report it, we will certainly provide update as we have a greater vision towards that timeline.

Appreciate it. Thank you. Yeah, thank you.

And we have reached our allotted time for questions. I would now like to turn the call back to Jason for any additional or closing remarks.

Thank you, operator. Before I close the call, I'd like to express my appreciation for all the Verica team members who make the results we announced today possible. I'd like to thank all of you for joining us for the meeting. We look forward to seeing some of you at the upcoming Jeffries Healthcare Conference next week and really appreciate the robust dialogue and questions from everyone today. Have a great night.

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.